2'-Deoxyadenosine monohydrate

2′-Deoxyadenosine monohydrate is an adenine nucleoside that inhibits glucose-stimulated insulin release. 2′-Deoxyadenosine monohydrate inhibits glucose-stimulated increases seen in islet cyclic AMP (cAMP) accumulation. 2'-Deoxyadenosine monohydrate activates caspase-3 and promotes apoptosis. 2'-Deoxyadenosine monohydrate inhibits the activity of S-adenosyl-L-homocysteine hydrolase (SAHH). 2'-Deoxyadenosine monohydrate inhibits the growth of various cells. 2'-Deoxyadenosine monohydrate has an anticancer effect on colon cancer^[1][2][3]. In Vitro:2′-Deoxyadenosine (10 mM) monohydrate does not inhibit insulin biosynthesis or [U-¹⁴C]glucose oxidation at concentrations of the nucleosides that gave maximal inhibition of insulin release. 2'-Deoxyadenosine monohydrate produces marked inhibition of the glucose-stimulated increases seen in islet cyclic AMP accumulation^[1].
2'-Deoxyadenosine (0.01-0.5 mM; 24-72 h) monohydrate inhibits the growth of LoVo human colon carcinoma cells in a concentration- and time-dependent manner and promotes apoptosis, as indicated by characteristic apoptotic morphology^[2].
2'-Deoxyadenosine monohydrate inhibits S-adenosyl-L-homocysteine hydrolase activity in crude extracts of L1210 leukemia cells in a time-dependent manner when assays are conducted in the presence of Deoxycoformycin (HY-A0006)^[3].
2'-Deoxyadenosine (0.1-2 mM; up to 3 h) monohydrate inhibits pig keratinocyte outgrowth, [³H] thymidine uptake, and mitosis^[4].
2'-Deoxyadenosine (0.1 mM; 4 days) monohydrate in combination with 1 μM dCF inhibits the growth of LoVo cells in a cell-density-dependent manner^[5].
2'-Deoxyadenosine (100 μM; 3 days) monohydrate in the presence of 3 μM Deoxycoformycin (HY-A0006) is toxic to rat chromaffin cells, causing apoptosis-like cell death, as shown by morphological changes, DNA fragmentation, and increased dATP levels^[6].
2'-Deoxyadenosine (0.1 mM) monohydrate in the presence of 0.01 mM dCF in vitro leads to a significant increase in dATP levels in mouse embryos^[7].